DOYLESTOWN, PA -- (MARKET WIRE) -- October 03, 2006 -- QuantRx® Biomedical Corporation (OTCBB: QTXB), an emerging leader in the research and development of medical diagnostic platforms and products, is pleased to announce that its affiliate company FluoroPharma, Inc. has begun Phase I clinical trials for CardioPET™, a novel cardiac viability imaging agent. The product has been developed to allow acute and chronic coronary artery disease to be assessed while patients are at rest.
